Percutaneous Renal Sympathetic Denervation for the Treatment of Resistant Hypertension with Heart Failure: First Experience in Korea

Jeong Hoon Yang, Seung-Hyuk Choi, and Hyeon-Cheol Gwon

Division of Cardiology, Department of Medicine, Cardiac and Vascular Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Received: 18 October 2012
Accepted: 15 February 2013

Address for Correspondence:
Seung-Hyuk Choi, MD
Cardiac and Vascular Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea
Tel: +82.2-3410-3419, Fax: +82.2-3410-3849
E-mail: sh1214.choi@samsung.com

INTRODUCTION

The renal sympathetic nervous system has been identified as a major contributor to the complex pathophysiology of hypertension and states of volume overload such as heart failure in humans (1, 2). Recently, catheter-based renal sympathetic denervation (RDN) has been introduced as a new technique to reduce blood pressure (BP) by denervation of efferent and afferent renal sympathetic nerve fibers using radiofrequency ablation (3, 4). Here we describe the first of these procedures performed in Korea on a 44-yr-old male with resistant hypertension complicated by heart failure. He successfully underwent percutaneous RDN with a significant reduction in BP after six months of follow-up.

CASE DESCRIPTION

Optimal BP could not be achieved in a 44-yr-old man with a seven-year history of hypertension despite antihypertensive therapy with four different drugs. He had a 30-pack-year smoking history with a body mass index of 33.4 kg/m², no history of diabetes, and a family history of early coronary artery disease. The patient first visited to our hospital with chronic headache on September 1, 2008. His antihypertensive medications consisted of hydrochlorothiazide 12.5 mg and felodipine 5 mg once a day, and carvedilol 25 mg and valsartan 160 mg twice a day. His average office BP was 170/115 mmHg and his 24-hr-ambulatory BP was 167/113 mmHg with a non-dipping profile (Fig. 1A).

The patient underwent the established clinical and laboratory evaluation to identify essential hypertension, and he did not have any secondary causes of hypertension (5). A physical examination revealed no abnormal findings. Resting electrocardiography revealed a normal sinus rhythm with left ventricular hypertrophy diagnosed using voltage criteria. N-terminal pro-brain natriuretic peptide, renin activity, aldosterone were 47.8 pg/mL (normal < 88 pg/mL), 0.5 ng/mL/hr (0.15 to 3.95 ng/mL/hr) and aldosterone was 4.0 ng/dL (1.0 to 27.3 ng/dL), respectively. In addition, other laboratory and his transthoracic echocardiographic findings were shown in Table 1. Computed tomography showed bilateral renal artery length > 20 mm, lumen diameter > 4 mm, and no significant atherosclerotic plaques.

He underwent percutaneous RDN under local anesthesia with midazolam and fentanyl. First, a 6 French sheath was inserted into the right femoral artery and 5000 units of heparin were injected intravenously. Renal angiography was performed through a 5 French pigtail catheter (Cordis, Miami Lakes, FL, USA). Then, a 6 French renal double curve guide catheter (Cordis, Miami Lakes, FL, USA) was inserted to engage the left renal artery. Using an ablation catheter (Symplicity, Ardian, Medtronic), five radiofrequency ablations (Fig. 2B) were delivered to the left renal artery and six (Fig. 2E) were delivered to the right renal...
Fig. 1. Monitoring of 24-hr ambulatory blood pressure (BP). (A) At baseline showing poorly controlled BP (average systolic/diastolic BP = 167/113 mm Hg). (B) After 6 months of follow-up showing suboptimally-controlled BP (average systolic/diastolic BP = 147/95 mmHg).

Table 1. Transthoracic echocardiographic and laboratory findings

| Parameter                                      | Baseline | 6 months |
|------------------------------------------------|----------|----------|
| Echocardiographic findings                     |          |          |
| Left ventricular ejection fraction (%)         | 38       | 39       |
| Left ventricular posterior wall thickness (cm) | 1.2      | 1.2      |
| Left ventricular end diastolic diameter (cm)  | 6.1      | 6.3      |
| Left ventricular end systolic diameter (cm)   | 4.3      | 4.6      |
| Left atrium volume index (mL/m²)              | 27.0     | 27.3     |
| Deceleration time (ms)                        | 227      | 216      |
| Septal E (m/s)                                | 0.59     | 0.37     |
| Septal A (m/s)                                | 0.35     | 0.51     |
| Septal E’ (m/s)                               | 0.056    | 0.042    |
| Septal A’ (m/s)                               | 0.052    | 0.061    |
| Septal E/E’                                   | 10.54    | 8.82     |
| S’ (m/s)                                      | 0.078    | 0.079    |

| Laboratory findings                           |          |          |
| Blood urea nitrogen (mg/dL)                   | 16.4     | 16.4     |
| Creatinine (mg/dL)                            | 1.14     | 1.20     |
| Estimated glomerular filtration rate (mL/min/1.73 m²) | 72      | 65.8     |
| Sodium (mM/L)                                 | 138      | 138      |
| Potassium (mM/L)                              | 4.0      | 4.1      |
| Albumin to creatinine ratio, urine (µg/mgCr)  | 179.6    | 17.5     |

This case is the first successful percutaneous RDN performed for the treatment of a hypertensive patient with congestive heart failure in Korea. Hyperactivation of the sympathetic nerve sys-
tem plays a major role in initiating and maintaining hypertension, and enhanced nerve activity in hypertensive patients may contribute to subsequent target organ damage such as left ventricular hypertrophy, congestive heart failure, and progressive renal damage (1, 2, 6-8). Surgical renal denervation has been performed to lower blood pressure in patients with hypertension, but the invasive nature of this approach is associated with a high incidence of complications (3). However, a percutaneous catheter-based device using radiofrequency ablation has recently been introduced to interrupt both efferent and afferent renal nerves located in the adventitia of the renal artery (9). The key clinical study supporting this technique, Symplicity HTN-2, was a multicenter, prospective, randomized controlled trial in patients aged 18-85 yr with a systolic blood pressure of 160 mm Hg or more (≥ 150 mm Hg in patients with type 2 diabetes), despite compliance with three or more antihypertensive drugs, showing a significant decrease in office BP of 32/12 mmHg after six months of follow-up in 49 patients who underwent RDN. Measurements of 24-hr ambulatory BP recordings were available for 20 patients in the RDN group in that study, showing a mean decrease of 11/7 mmHg at six months (10). In our case, the drop in office BP was 49/37 mmHg with a decrease in 24-hr ambulatory BP of 20/18 mmHg after six months of follow-up.

Considering data obtained from Western populations (3, 10, 11), our results suggest that percutaneous RDN could also be an effective and safe strategy for the treatment of resistant hypertension in Asian populations. Furthermore, in hypertensive patients with heart failure and left ventricular systolic dysfunction like our patient, the beneficial effects of this procedure might extend beyond a decrease in BP and involve the repair of end organ damage because conditions such as hypertension, heart failure, and kidney injury are commonly associated with sodium retention or systemic sympathetic hyperactivity albeit by different mechanisms (3). Our patient’s microalbuminuria was improved although there was no change in his left ventricular systolic function. Further research is needed to investigate the benefit of this procedure for the treatment of various conditions such as heart failure and hypertension.

In summary, we reported the first successful experience with percutaneous RDN as a new technique for the treatment of hypertension. Our findings indicate that percutaneous RDN might be an effective and safe therapeutic tool in Asian populations.
with resistant hypertension.

REFERENCES

1. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54: 1195-201.

2. DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension 2004; 43: 147-50.

3. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.

4. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60: 419-24.

5. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1751-62.

6. Thomas G, Shishehbor MH, Bravo EL, Nally JV. Renal denervation to treat resistant hypertension: guarded optimism. Cleve Clin J Med 2012; 79: 501-10.

7. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724-8.

8. Davies JE, Manisty CH, Petracco R, Barron AJ, Unsworth B, Mayet J, Hamady M, Hughes AD, Sever PS, Sobotka PA, et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot Study. Int J Cardiol 2013; 162: 189-92.

9. Sobotka PA, Krum H, Böhm M, Francis DP, Schlaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep 2012; 14: 285-92.

10. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.

11. Voskuil M, Verloop WL, Blankestijn PJ, Agostoni P, Stella PR, Doeven dans PA. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J 2011; 19: 319-23.